Rezolute to Participate in Upcoming Investor Conferences
August 27 2024 - 8:00AM
Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a
late-stage rare disease company focused on significantly
improving outcomes for individuals with hypoglycemia caused by
hyperinsulinism (HI), today announced that management will
participate in the following investor conferences:
Event: H.C. Wainwright 26th
Annual Global Investment ConferenceDate: September
9-11, 2024
Event: Cantor Global Healthcare
ConferenceDate: September 17-19, 2024
Management will be participating in one-on-one
investor meetings throughout the conferences. Investors interested
in scheduling a meeting with the Rezolute management team should
contact their H.C. Wainwright and Cantor representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company
focused on significantly improving outcomes for individuals with
hypoglycemia caused by hyperinsulinism (HI). The Company’s
antibody therapy, RZ358 (ersodetug), is designed to treat all forms
of HI and has shown substantial benefit in clinical trials and
real-world use for the treatment of congenital hyperinsulinism
(cHI) and tumor hyperinsulinism (tHI).
Contacts:
Rezolute, Inc.Christen
Baglaneascbaglaneas@rezolutebio.com508-272-6717
LHA Investor RelationsTirth T.
Pateltpatel@lhai.com212-201-6614
Rezolute (NASDAQ:RZLT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Rezolute (NASDAQ:RZLT)
Historical Stock Chart
From Sep 2023 to Sep 2024